Payment overview · 2025
General Payments
$723.81
41 reported records · 18 companies
Healthcare provider profile · identity verified
William R. Gammon, MD
Allopathic & Osteopathic Physicians|Family Medicine · MYRTLE BEACH, SC · NPI 1164419941
Verified facts
What the public records show
CMS Open Payments records show William R. Gammon, MD received $723.81 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.08 | 22.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.42 | 10.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.26 | 8.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.20 | 8.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.28 | 6.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.60 | 5.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.33 | 5.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.75 | 5.3% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.27 | 3.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.48 | 3.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.53 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.84 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.89 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.73 | 2.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.22 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.49 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.23 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.21 | 1.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $723.81 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.42 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.39 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.13 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.75 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.71 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 149 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 225 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 723 | 227 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 141 |
| Prednisone | Prednisone | 390 | 232 |
| Lisinopril | Lisinopril | 359 | 111 |
| Losartan Potassium | Losartan Potassium | 343 | 111 |
| Alprazolam | Alprazolam | 330 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 322 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 78 |
| Omeprazole | Omeprazole | 274 | 84 |
| Simvastatin | Simvastatin | 259 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 76 |
| Gabapentin | Gabapentin | 228 | 66 |
| Metformin Hcl | Metformin Hcl | 222 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 206 | 49 |
| Tramadol Hcl | Tramadol Hcl | 200 | 45 |
| Trazodone Hcl | Trazodone Hcl | 183 | 68 |
| Furosemide | Furosemide | 175 | 58 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 174 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 28 |
| Memantine Hcl | Memantine Hcl | 156 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 48 |
| Mounjaro | Tirzepatide | 153 | 29 |
| Ozempic | Semaglutide | 152 | 39 |
| Meloxicam | Meloxicam | 150 | 40 |
| Eliquis | Apixaban | 149 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 146 | 47 |
| Allopurinol | Allopurinol | 140 | 40 |
| Sertraline Hcl | Sertraline Hcl | 140 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 19 |
| Azithromycin | Azithromycin | 137 | 97 |
| Montelukast Sodium | Montelukast Sodium | 135 | 39 |
| Farxiga | Dapagliflozin Propanediol | 112 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 37 |
| Carvedilol | Carvedilol | 109 | 35 |
| Jardiance | Empagliflozin | 108 | 33 |
| Metformin Hcl Er | Metformin Hcl | 107 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 55 |
| Bupropion Xl | Bupropion Hcl | 97 | 25 |
| Famotidine | Famotidine | 97 | 37 |
| Celecoxib | Celecoxib | 91 | 33 |
| Ezetimibe | Ezetimibe | 90 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 26 |
| Donepezil Hcl | Donepezil Hcl | 88 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 71 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 19 |
| Irbesartan | Irbesartan | 79 | 19 |
| Potassium Chloride | Potassium Chloride | 76 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 29 |
| Atenolol | Atenolol | 73 | 19 |
| Glimepiride | Glimepiride | 72 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 19 |
| Valacyclovir | Valacyclovir Hcl | 68 | 16 |
| Lorazepam | Lorazepam | 64 | 20 |
| Synthroid | Levothyroxine Sodium | 64 | 18 |
| Diazepam | Diazepam | 63 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 23 |
| Clonazepam | Clonazepam | 62 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 22 |
| Finasteride | Finasteride | 59 | 21 |
| Meclizine Hcl | Meclizine Hcl | 59 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 15 |
| Valsartan | Valsartan | 54 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 13 |
| Spironolactone | Spironolactone | 48 | 18 |
| Baclofen | Baclofen | 47 | 11 |
| Fenofibrate | Fenofibrate | 47 | 13 |
| Temazepam | Temazepam | 46 | 14 |
| Chlorthalidone | Chlorthalidone | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 16 |
| Glipizide | Glipizide | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 35 |
| Fluconazole | Fluconazole | 43 | 24 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 14 |
| Linzess | Linaclotide | 40 | 16 |
| Ramipril | Ramipril | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | 11 |
| Testosterone | Testosterone | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 28 |
| Methylphenidate Hcl | Methylphenidate Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 19 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Colchicine | Colchicine | 24 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $723.81 · 41 records | Novo Nordisk Inc | ABRYSVO, Auvelity, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INJECTAFER, INSPIRE, JARDIANCE, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, WATCHMAN Access System, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error